146829-56-3

Basic information

• Product Name: 2-AMINO-5-FLUOROBENZALDEHYDE
• Synonyms: 2-AMINO-5-FLUOROBENZALDEHYDE
• CAS NO: 146829-56-3
• Molecular Formula: C₇H₆FNO
• Molecular Weight: 139.13
• Mol File: 146829-56-3.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 260℃
• Flash Point: 111℃
• Appearance: /
• Density: 1.293
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-AMINO-5-FLUOROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-FLUOROBENZALDEHYDE(146829-56-3)
• EPA Substance Registry System: 2-AMINO-5-FLUOROBENZALDEHYDE(146829-56-3)

Safety Data

• Hazardous Substances Data: 146829-56-3(Hazardous Substances Data)

Usage

Uses

2-Amino-5-fluorobenzaldehyde is a building block used in various synthetic preparations. It was used as a reactant in the stereoselective preparation of aryltetrahydroquinolines via gold-phosphine catalyzed heterocyclization of aminobenzaldehyde with alkynes.

Upstream product

• 748805-85-8 (2-amino-5-fluorophenyl)methanol 
• 94569-84-3 2-bromo-5-fluorobenzaldehyde 
• 287121-32-8 (5-Fluoro-2-nitrophenyl)-methanol 
• 446-08-2 2-amino-5-fluorobenzoic acid 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 

Downstream Products

• 690664-26-7 C₁₀H₁₀FNO₂ 
• 1395473-88-7 (S)-6-fluoro-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoline 
• 56341-41-4 5-fluoroindol-2(3H)-one 
• 71083-44-8 6-fluoroquinoline-3-carbonitrile 

Relevant articles and documents

Design, synthesis and in vitro anticancer activity of novel quinoline and oxadiazole derivatives of ursolic acid

A series of new quinoline derivatives of ursolic acid were designed and synthesized in an attempt to develop potential anticancer agents. The structures of these compounds were identified by 1H NMR, 13C NMR, IR and ESI-MS spectra analysis. The target compounds were evaluated for their in vitro cytotoxicity against three human cancer cell lines (MDA-MB-231, Hela and SMMC-7721). From the results, compounds 3a–d displayed significant antitumor activity against three cancer cell lines. Especially, compound 3b was found to be the most potent derivative with IC50 values of 0.61 ± 0.07, 0.36 ± 0.05, 12.49 ± 0.08 μM against MDA-MB-231, HeLa and SMMC-7721 cells, respectively, stronger than positive control etoposide. Furthermore, the Annexin V-FITC/PI dual staining assay revealed that compound 3b could significantly induce the apoptosis of MDA-MB-231 cells in a dose-dependent manner. The cell cycle analysis also indicated that compound 3b could cause cell cycle arrest of MDA-MB-231 cells at G0/G1 phase.

Silver-Catalyzed Three-Component Coupling Reaction of Amines, 2-Isocyanobenzaldehydes, and 2,2,2-Trifluorodiazoethane and Synthesis of Trifluoromethyl-Substituted Indolo[1,2-c]quinazolines

A silver-catalyzed three-component coupling reaction of amines, 2-isocyanobenzaldehydes, and 2,2,2-trifluorodiazoethane has been developed. This reaction provides an efficient method for the construction of CF3-containing dihydroquinazolines. On the basis of this reaction, using trifluorodiazoethyl-substituted dihydroquinazolines as synthons, trifluoromethyl-substituted indolo[1,2-c]quinazolines were prepared in high yields via a TBHP/KI-mediated sequential intramolecular cyclization and aromatization process. (Figure presented.).

Repurposing an Aldolase for the Chemoenzymatic Synthesis of Substituted Quinolines

Quinoline derivatives are important natural products and pharmaceuticals, but their synthesis can be challenging due to poor yields, harsh reaction conditions, and instability of starting materials. Here we report the chemoenzymatic synthesis of quinaldic acids under mild conditions using an aldolase, trans-o-hydroxybenzylidenepyruvate hydratase-aldolase (NahE, or HBPA). A series of 2-aminobenzaldehydes derived from reduction of the corresponding nitro analogue were reacted with pyruvate in the presence of NahE to give substituted quinolines in up to 93% isolated yield. This reaction differs from the aldol condensation catalyzed by NahE in vivo, instead resembling the heterocycle formation catalyzed by its homologue, dihydrodipicolinate synthase.

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.